2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 295

Reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index Among Dermatologists, Rheumatologists, and Neurologists

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 827

Reliability of the Quantitative Assessment of Peripheral Blood Perfusion By Laser Speckle Contrast Analysis in a Systemic Sclerosis Cohort

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster I

9:00AM-11:00AM: Abstract Number: 637

Repeated B Lymphocyte Depletion Therapy with Rituximab in Sjögren’s Syndrome: A Single Center Experience

Sjögren's Syndrome Poster I: Clinical Insights into Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 727

Repository Corticotropin Injection (H.P. Acthar® Gel) Attenuates Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE) Requiring Corticosteroids

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

9:00AM-11:00AM: Abstract Number: 203

Rescue of Copa Syndrome Cellular Phenotype By Autophagy Modifying Drugs

Innate Immunity and Rheumatic Disease Poster I

9:00AM-11:00AM: Abstract Number: 151

Residual Synovitis in Ultrasound (US) Is Associated with an Evolution Towards Rheumatoid Arthritis (RA) in Patients with Inflammatory Polyarthralgia without ANTI-Citrulinated Antibodies (ACPA)

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

9:00AM-11:00AM: Abstract Number: 302

Resource Utilization in a US Sample of Patients with Sporadic Inclusion Body Myositis

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 344

Results of a Phase 2 Clinical Trial to Evaluate the Effects of Romosozumab in Japanese Women with Postmenopausal Osteoporosis

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 433

Rheumatoid Arthritis (RA) Biologic Switching and Cycling in a Large US Managed Care Population

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 87

Rheumatoid Arthritis (RA) Risk Gene CCR6 Polymorphism: Drug-Induced “Reversal” of ER Binding and the Expression of Inflammatory Mediators -Potential Molecular Mechanism Links Between Estrogen and RA

Genetics, Genomics and Proteomics Poster I

9:00AM-11:00AM: Abstract Number: 35

Rheumatoid Arthritis As a Risk Factor for Cardiovascular Events Following Hospitalized Pneumonia; A Population-Based Cohort Study

Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 184

Rheumatologists and Musculoskeletal Ultrasound: Discrepancy Between Attitudes, Desire and Reality in Routine Practice in South East England

Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

9:00AM-11:00AM: Abstract Number: 129

Rheumatologists’ Approaches to Diagnosis and Treatment of Depression

Health Services Research Poster I: Diagnosis, Management and Treatment Strategies

9:00AM-11:00AM: Abstract Number: 212

Rising Incidence and Prevalence of Gout in the Canadian General Population

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 868

Risk Factors for Cytomegalovirus Reactivation in Patients with Antineutrophil Cytoplasmic Antibody -Associated Vasculitis

Vasculitis Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].